- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03398785
Adrenal Artery Ablation Treats Primary Aldosteronism
An Open-label, Prospective, Controlled Clinical Trial on Effects and Safety of Adrenal Artery Ablation (Triple A) for Primary Aldosteronism
Primary aldosteronism (PA) is one of the most common cause of endocrine and resistant hypertension. Current studies have shown that the activation of the renin-angiotensin-aldosterone system (RAAS) and the increased sympathetic nerve activity in the central or local tissue are the key mechanisms of high blood pressure and its organ damages.
The classical method for diagnosis of primary aldosteronism depends on the detection of peripheral venous blood aldosterone level, which is incapable of accurate positioning diagnosis. On the other hand, the current guidelines recommend that surgery and aldosterone receptor inhibitors were the only treatment for primary aldosteronism. However, only about 35% of aldosterone tumors and a small part of unilateral adrenal hyperplasia can be treated by surgery. More than 60% of idiopathic aldosteronism and bilateral adrenal hyperplasia need long-term drug therapy. However, long-term aldosterone inhibitor treatment may also cause hyperkalemia, male breast hyperplasia, female hirsutism and other adverse reactions.
Therefore, the investigators proposed that endovascular chemical partial ablation of the adrenal gland can lower the aldosterone level, reduce the blood pressure and recover the potassium metabolism balance. In order to confirm the above effects, the investigators conduct an open, prospective, positive controlled study in patients with primary aldosteronism patients (including aldosterone, idiopathic aldosteronism and adrenal hyperplasia). The effects on blood pressure, blood electrolytes, adrenal hormones, metabolic indexes, target organ damages were observed to explore the efficacy and safety of the endovascular ablation of the adrenal gland in the treatment of primary aldosteronism.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 400042
- The third hospital affiliated to the Third Military Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Primary Aldosteronis diagnosed by increased Renin ratio (ARR) and serum aldosterone levels ≥15 ng / dl, and confirmed by saline injection test or captopril inhibition test.
- Idiopathic aldosteronism, bilateral adrenal hyperplasia, and unilateral adrenal hyperplasia with no superior secretion confirmed with adrenal CT and adrenal venous blood (AVS).
- The patients was diagnosed with aldosteronoma or unilateral adrenal hyperplasia but refused to surgical excision.
- Signed informed consent and agreed to participate in this study.
Exclusion Criteria:
- Aldosterone cancer.
- Hyperkalemia.
- Renal failure or the following history of nephropathy: serum creatinine 1.5 times higher than the upper limit; dialysis history; or nephrotic syndrome.
- Secondary hypertension except the primary aldosteronism.
- Adrenergic insufficiency.
- Heart failure with NYHA grade Ⅱ-Ⅳ grade or unstable angina, severe cardiovascular and cerebrovascular stenosis, myocardial infarction, intracranial aneurysm, stroke and other acute cardiovascular events.
- Acute infections, tumors and severe arrhythmias, psychiatric disorders, drugs or alcohol addicts.
- Liver dysfunction or the following history of liver disease: AST or ALT 2 times higher than the upper limit, liver cirrhosis, history of hepatic encephalopathy, esophageal variceal history or portal shunt history.
- Coagulation dysfunction.
- Pregnant women or lactating women.
- Participated in other clinical trials or admitted with other research drugs within 3 months prior to the trial.
- Any surgical or medical condition which can significantly alter the absorption, distribution, metabolism, or excretion of any study drug.
- Allergy or any contraindications for the study drugs, contrast agents and alcohol.
- Refused to sign informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Intevention
Adrenal Artery Ablation
|
Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
|
NO_INTERVENTION: Control
No intervention, but treated with standard anti-hypertensive drigs
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of 24-h average systolic blood pressure compared with the baseline
Time Frame: 24 weeks
|
Change of 24-h average systolic blood pressure compared with the baseline at the end of the study (24 weeks) in the intervention group.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of 24-h average systolic blood pressure between two groups
Time Frame: 24 weeks
|
Change of 24-h average systolic blood pressure between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Change of anti-hypertensive regimen between two groups
Time Frame: 24 weeks
|
Change of number, classes, and combinations of classes of antihypertensive drugs between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure between two groups
Time Frame: 24 weeks
|
Change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Change of office systolic and diastolic pressure between two groups
Time Frame: 24 weeks
|
Change of office systolic and diastolic pressure between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Change of blood electrolytes(serum potassium and natrium in mmol/L)
Time Frame: 24 weeks
|
Change of blood electrolytes(serum potassium and natrium in mmol/L) compared with baseline, and between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Change of plasma aldosterone and 24-h urine aldosterone
Time Frame: 24 weeks
|
Change of plasma aldosterone and 24-h urine aldosterone compared with baseline, and between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Change of plasma renin
Time Frame: 24 weeks
|
Change of plasma renin compared with baseline, and between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Change of plasma cortisol and 24-h urine cortisol
Time Frame: 24 weeks
|
Change of plasma cortisol and 24-h urine cortisol compared with baseline, and between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Change of liver enzymes (ALT, AST)
Time Frame: 24 weeks
|
Change of liver enzymes (ALT, AST) compared with baseline, and between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Change of serum creatinine
Time Frame: 24 weeks
|
Change of serum creatinine compared with baseline, and between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Change of fasting blood glucose
Time Frame: 24 weeks
|
Change of fasting blood glucose in mmol/L compared with baseline, and between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Change of lipids profiles (TC, HDL-C, LDL-C, TG) in mmol/L
Time Frame: 24 weeks
|
Change of lipids profiles (Total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride) in mmol/L compared with baseline, and between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of testosterone and estrogen levels
Time Frame: 24 weeks
|
Change of testosterone and estrogen levels compared with baseline, and between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Change of 24-h urine microalbumin, microalbumin/creatinine ratio
Time Frame: 24 weeks
|
Change of 24-h urine microalbumin, microalbumin/creatinine ratio compared with baseline, and between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Change of parameters assessed by echocardiography (IVSd、IVSs、LVPWd, LVPWs, LVEDD, LVEF, LVM)
Time Frame: 24 weeks
|
Change of parameters assessed by echocardiography (IVSd、IVSs、LVPWd, LVPWs, LVEDD, LVEF, LVM) compared with baseline, and between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Change of carotid intima-media thickness assessed by carotid ultrasound
Time Frame: 24 weeks
|
Change of carotid intima-media thickness(CIMT) assessed by carotid ultrasound compared with baseline, and between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Change of electrocardiogram manifestations
Time Frame: 24 weeks
|
Change of electrocardiogram manifestations(heart rhythms, heart rates and arrhythmia ) compared with baseline, and between the intervention and control group at the end of the study (24 weeks)
|
24 weeks
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Endocrine System Diseases
- Adrenocortical Hyperfunction
- Adrenal Gland Diseases
- Hypertension
- Hyperaldosteronism
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-Agonists
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Epinephrine
- Racepinephrine
- Epinephryl borate
Other Study ID Numbers
- Triple A-PA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Endovascular chemical Ablation of Adrenal Gland
-
Third Military Medical UniversityUnknown
-
Third Military Medical UniversityRecruitingHypertension | Primary AldosteronismChina
-
Third Military Medical UniversityCompletedHypertension | Primary AldosteronismChina
-
Third Military Medical UniversityUnknown
-
Alberta Health servicesOttawa Hospital Research Institute; Jewish General Hospital; CancerCare Manitoba and other collaboratorsCompleted
-
Urological Research Network, LLCRecruitingMRI | Urinary Incontinence | Prostate Cancer | Ultrasound | Ablation | Sexual Function Disturbances | Prostate Biopsy | Adverse Effects Surgery | Urinary Function DisordersUnited States
-
The University of Hong KongRecruitingPain | Pancreatic Neoplasms | Pain Management | Cancer of Pancreas | Cancer-Associated PainHong Kong
-
Haukeland University HospitalRecruitingPrimary Aldosteronism | Aldosterone-Producing AdenomaNorway
-
University of AarhusAarhus University HospitalCompletedCarcinoma, Hepatocellular | Neuroendocrine TumorsDenmark